mTOR inhibition attenuates dextran sulfate sodium-induced colitis by suppressing T cell proliferation and balancing TH1/TH17/Treg profile

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Hu, Shurong ^a   Chen, Mengmeng ^a   Wang, Yilin ^b   Wang, Zhengting ^a   Pei, Yaofei ^a   Fan, Rong ^a   Liu, Xiqiang ^c   Wang, Lei ^a   Zhou, Jie ^a   Zheng, Sichang ^a   Zhang, Tianyu ^a   Lin, Yun ^a   Zhang, Maochen ^a   Tao, Ran ^c   Zhong, Jie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 8055; DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; AUTACOID; MORPHOLINE DERIVATIVE; MTOR PROTEIN, MOUSE; NONSTEROID ANTIINFLAMMATORY AGENT; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; LAMINA PROPRIA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECTUM HEMORRHAGE; REGULATORY T LYMPHOCYTE; SPLEEN; TH1 CELL; TH17 CELL; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TOR SERINE-THREONINE KINASES;

EID: 84967190717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154564     Document Type: Article

References (71)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621. doi: 10.1146/annurev-immunol-030409-101225 PMID: 20192811
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 390-407. PMID: 16819502
3. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 2058-2069. PMID: 17561966
4. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med. 2009; 15: 199-207. doi: 10.1016/j.molmed.2009.03.002 PMID: 19362058
5. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005; 206: 260-276. PMID: 16048554
6. Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004; 173: 3119-3130. PMID: 15322172
7. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006; 212: 256-271. PMID: 16903919
8. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007; 204: 1849-1861. PMID: 17635957
9. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006; 116: 1310-1316. PMID: 16670770
10. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066-2078. doi: 10.1056/NEJMra0804647 PMID: 19923578
11. Wu X, Dou Y, Yang Y, Bian D, Luo J, Tong B, et al. Arctigenin exerts anti-colitis efficacy through inhibiting the differentiation of Th1 and Th17 cells via an mTORC1-dependent pathway. Biochem Pharmacol. 2015; 96: 323-336. doi: 10.1016/j.bcp.2015.06.008 PMID: 26074264
12. Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, et al. TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating Both T-Helper 1 and T-Helper 17 Activation. Gastroenterology. 2008; 135: 552-567. doi: 10.1053/j.gastro.2008.04.037 PMID: 18598698
13. Heiseke AF, Faul AC, Lehr HA, Förster I, Schmid RM, Krug AB, et al. CCL17 Promotes Intestinal Inflammation in Mice and Counteracts Regulatory T Cell-Mediated Protection From Colitis. Gastroenterology. 2012; 142: 335-345. doi: 10.1053/j.gastro.2011.10.027 PMID: 22057112
14. Sokol H, Conway KL, Zhang M, Choi M, Morin B, Cao Z, et al. Card9 Mediates Intestinal Epithelial Cell Restitution, T Helper 17 Responses, and Control of Bacterial Infection in Mice. Gastroenterology. 2013; 145: 591-601. doi: 10.1053/j.gastro.2013.05.047 PMID: 23732773
15. Mudter J, Yu J, Zufferey C, Brüstle A, Wirtz S, Weigmann B, et al. IRF4 Regulates IL-17A Promoter Activity and Controls RORct dependent Th17 Colitis In Vivo. Inflamm Bowel Dis. 2011; 17: 1343-1358. doi: 10.1002/ibd.21476 PMID: 21305677
16. Brown JB, Cheresh P, Zhang Z, Ryu H, Managlia E, Barrett TA. P-selectin Glycoprotein Ligand-1 Is Needed for Sequential Recruitment of T-helper 1 (Th1) and Local Generation of Th17 T Cells in Dextran Sodium Sulfate (DSS) Colitis. Inflamm Bowel Dis. 2012; 18: 323-332. doi: 10.1002/ibd.21779 PMID: 22009715
17. Ustyugova IV, Zhi L, Wu MX. Reciprocal Regulation of the Survival and Apoptosis of Th17 and Th1 Cells in the Colon. Inflamm Bowel Dis. 2012; 18: 333-343. doi: 10.1002/ibd.21772 PMID: 21618360
18. Wurbel MA, McIntire MG, Dwyer P, Fiebiger E. CCL25/CCR9 Interactions Regulate Large Intestinal Inflammation in a Murine Model of Acute Colitis. PLoS One. 2011; 6: e16442. doi: 10.1371/journal.pone.0016442 PMID: 21283540
19. Morgan ME, Zheng B, Koelink PJ, van de Kant HJ, Haazen LC, van Roest M, et al. New perspective on dextran sodium sulfate colitis: antigen-specific T cell development during intestinal inflammation. PLoS One. 2013; 8: e69936. doi: 10.1371/journal.pone.0069936 PMID: 23936123
20. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009; 30: 832-844. doi: 10.1016/j.immuni.2009.04.014 PMID: 19538929
21. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+ Foxp3+ regulatory T cells. Blood. 2011; 118: 2342-2350. doi: 10.1182/blood-2010-10-313684 PMID: 21734238
22. Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, et al. Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood. 2012; 119: 5898-5908. doi: 10.1182/blood-2011-12-396119 PMID: 22538855
23. Farkas S, Hornung M, Sattler C, Guba M, Steinbauer M, Anthuber M, et al. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis. 2006; 21: 747-753. PMID: 16228179
24. Matsuda C, Ito T, Song J, Mizushima T, Tamagawa H, Kai Y, et al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol. 2007; 148: 348-359. PMID: 17437423
25. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009; 9: 324-337. doi: 10.1038/nri2546 PMID: 19390566
26. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012; 30: 39-68. doi: 10.1146/annurev-immunol-020711-075024 PMID: 22136167
27. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009; 284: 8023-8032. doi: 10.1074/jbc.M900301200 PMID: 19150980
28. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010; 70: 288-298. doi: 10.1158/0008-5472.CAN-09-1751 PMID: 20028854
29. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69: 238-249. PMID: 8350599
30. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut. 2002; 50: 507-512. PMID: 11889071
31. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature. 2008; 455: 808-812. doi: 10.1038/nature07240 PMID: 18716618
32. Chen Z, Kim SJ, Chamberlain ND, Pickens SR, Volin MV, Volkov S, et al. The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. J Immunol. 2013; 190: 5256-66. doi: 10.4049/jimmunol.1201675 PMID: 23606539
33. Bhattacharya P, Fan J, Haddad C, Essani A, Gopisetty A, Elshabrawy HA, et al. A novel pancreatic β-cell targeting bispecific-antibody (BsAb)can prevent the development of type 1 diabetes in NOD mice. Clin Immunol. 2014; 153: 187-98. doi: 10.1016/j.clim.2014.04.014 PMID: 24792135
34. Martin B, Banz A, Bienvenu B, Cordier C, Dautigny N, Bécourt C, et al. Suppression of CD4+ T lymphocyte effector functions by CD4+CD25+ cells in vivo. J Immunol. 2004; 172: 3391-3398. PMID: 15004137
35. Karlsson F, Robinson-Jackson SA, Gray L, Zhang S, Grisham MB. Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis. Methods Mol Biol. 2011; 677: 47-61. doi: 10.1007/978-1-60761-869-0-4 PMID: 20941602
36. Martin B, Auffray C, Delpoux A, Pommier A, Durand A, Charvet C, et al. Highly self-reactive naive CD4 T cells are prone to differentiate into regulatory T cells. Nat Commun. 2013; 4: 2209. doi: 10.1038/ncomms3209 PMID: 23900386
37. Veltkamp C, Ruhwald R, Giesem T, Autschbach F, Kaden I, Veltkamp R, et al. CD4+CD25+ cell depletion from the normal CD4+ T cell pool prevents tolerance toward the intestinal flora and leads to chronic colitis in immunodeficient mice. Inflamm Bowel Dis. 2006; 12: 437-446. PMID: 16775487
38. Kitani A, Xu L. Regulatory T cells and the induction of IL-17. Mucosal Immunol. 2008; Suppl 1: : S43-46. doi: 10.1038/mi.2008.51 PMID: 19079228
39. +T cells: differentiation and functions. Clin Dev Immunol. 2012; 2012: 925135 doi: 10.1155/2012/925135 PMID: 22474485
40. Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol. 2013; 25: 305-312. doi: 10.1016/j.smim.2013.10.009 PMID: 24211039
41. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004; 10: 801-805. PMID: 15286781
42. Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R. CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci. 2011; 56: 376-386. doi: 10.1007/s10620-010-1286-2 PMID: 20521112
43. Ito H. Treatment of Crohn's disease with anti-IL-6 receptor antibody. J Gastroenterol. 2005; 40 Suppl 16:32-4. PMID: 15902961
44. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012; 367: 1519-1528. doi: 10.1056/NEJMoa1203572 PMID: 23075178
45. Yin H, Li X, Zhang B, Liu T, Yuan B, Ni Q, et al. Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis. Immunology. 2013; 139: 494-502. doi: 10.1111/imm.12096 PMID: 23480027
46. Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol. 2007; 19: 162-172. PMID: 17383196
47. Yurchenko E, Shio MT, Huang TC, Da Silva Martins M, Szyf M, Levings MK, et al. Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One. 2012; 7: e35572. doi: 10.1371/journal.pone.0035572 PMID: 22545118
48. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009; 2: pe24. doi: 10.1126/scisignal.267pe24 PMID: 19383975
49. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19 +CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010; 32: 129-40. doi: 10.1016/j.immuni.2009.11.009 PMID: 20079667
50. Maseda D, Candando KM, Smith SH, Kalampokis I, Weaver CT, Plevy SE, et al. Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice. J Immunol. 2013; 191: 2780-95. doi: 10.4049/jimmunol.1300649 PMID: 23918988
51. Lund FE,Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010; 10: 236-47. doi: 10.1038/nri2729 PMID: 20224569
52. Salinas GF, Braza F, Brouard S, Tak PP, Baeten D. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin Immunol. 2013; 146: 34-45. doi: 10.1016/j.clim.2012.10.005 PMID: 23202542
53. Hua F, Ji L, Zhan Y, Li F, Zou S, Chen L,et al. Aberrant frequency of IL-10-producing B cells and its association with Treg/Th17 in adult primary immune thrombocytopenia patients. Biomed Res Int. 2014; 2014:571302. doi: 10.1155/2014/571302 PMID: 25057496
54. Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013; 5: 173ra23. doi: 10.1126/scitranslmed.3005407 PMID: 23427243
55. Ashour HM,Niederkorn JY. Expansion of B cells is necessary for the induction of T-cell tolerance elicited through the anterior chamber of the eye. Int Arch Allergy Immunol. 2007; 144: 343-6. PMID: 17671393
56. Ashour HM,Seif TM. The role of B cells in the induction of peripheral T cell tolerance. J Leukoc Biol. 2007; 82: 1033-9. PMID: 17656652
57. Bhattacharya P, Gopisetty A, Ganesh BB, Sheng JR, Prabhakar BS. GM-CSF induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J Leukoc Biol. 2011; 89: 235-49. doi: 10.1189/jlb.0310154 PMID: 21048215
58. Gopisetty A, Bhattacharya P, Haddad C, Bruno JC Jr, Vasu C, Miele L, et al.OX40L/Jagged1 cosignaling by GM-CSF-induced bone marrow-derived dendritic cells is required for the expansion of functional regulatory T cells. J Immunol. 2013; 190: 5516-25. doi: 10.4049/jimmunol.1202298 PMID: 23630352
59. Gangi E, Vasu C, Cheatem D, Prabhakar BS. IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol. 2005; 174: 7006-13. PMID: 15905543
60. Rowin J, Thiruppathi M, Arhebamen E, Sheng J, Prabhakar BS, Meriggioli MN. Granulocyte macrophage colony stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012; 46: 449-53. doi: 10.1002/mus.23488 PMID: 22907239
61. Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alharshawi K, Kumar P, Prabhakar BS. GM-CSF: An immune modulatory cytokine that can suppress autoimmunity. Cytokine. 2015; 75: 261-71. doi: 10.1016/j.cyto.2015.05.030 PMID: 26113402
62. Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alharshawi K, Elshabrawy H, et al. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J Interferon Cytokine Res. 2015; 35: 585-99. doi: 10.1089/jir.2014.0149 PMID: 25803788
63. Bernasconi E, Favre L, Maillard MH, Bachmann D, Pythoud C, Bouzourene H, et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis. 2010; 16: 428-41. doi: 10.1002/ibd.21072 PMID: 19639560
64. Sainathan SK, Hanna EM, Gong Q, Bishnupuri KS, Luo Q, Colonna M, et al. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis. 2008; 14: 88-99. PMID: 17932977
65. Gathungu G, Kim MO, Ferguson JP, Sharma Y, Zhang W, Ng SM, et al. Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease. Inflamm Bowel Dis. 2013; 19: 1671-80. doi: 10.1097/MIB.0b013e318281f506 PMID: 23749272
66. Gaudreau S, Guindi C, Menard M, Besin G, Dupuis G, Amrani A. Granulocyte macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol. 2007; 179: 3638-47. PMID: 17785799
67. Kared H, Leforban B, Montandon R, Renand A, Layseca Espinosa E, Chatenoud L, et al. Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood. 2008; 112: 2575-8. doi: 10.1182/blood-2008-02-140681 PMID: 18617637
68. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia. 2012; 26: 1195-202. doi: 10.1038/leu.2011.339 PMID: 22143671
69. Li Q, Song XM, Ji YY, Jiang H, Xu LG. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem Biophys Res Commun. 2013; 440: 701-706. doi: 10.1016/j.bbrc.2013.09.130 PMID: 24103749
70. Sini P, James D, Chresta C, Guichard S. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy. 2010; 6: 553-554. doi: 10.4161/auto.6.4.11671 PMID: 20364113
71. Rosborough BR, Raich-Regue D, Liu Q, Venkataramanan R, Turnquist HR, Thomson AW. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014; 14: 2173-2180. doi: 10.1111/ajt.12799 PMID: 25307040